文献速递前列腺癌

高龄预测主动监测中穿刺与根治术病理分级升级至侵袭性前列腺癌

Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
PubMed 文献 · J Urol · 2019-01-01

该研究随访1625例NCCN极低危或低危前列腺癌主动监测患者,发现年龄越大,穿刺分级升级至GG3及以上风险越高,5年发生率在<60岁、60-69岁、≥70岁分别为4%、7%、14%;穿刺升级后行根治术者,高龄亦与根治术分级升级相关。

要点

  • 主动监测中高龄与穿刺分级升级至GG3及以上独立相关(每10年HR 2.19)。
  • 5年穿刺升级至GG3及以上率:<60岁4%、60-69岁7%、≥70岁14%。
  • 穿刺升级后根治术病理分级升级率在高龄者更高。

核心结论

  • 主动监测患者诊断时年龄越大,穿刺分级升级至GG3及以上及根治术分级升级风险越高。
  • 对多数高龄男性,主动监测仍比观察等待更合适。

研究设计与样本

  • 1995至2016年随访1625例41至81岁NCCN极低危(68%)或低危(32%)前列腺癌主动监测患者。
  • 采用竞争风险分析评估入组年龄与穿刺分级升级的关联。

主要发现

  • 5年穿刺分级升级至GG3及以上发生率:<60岁4%、60-69岁7%、≥70岁14%(p<0.001)。
  • 单因素分析高龄与穿刺升级至GG3及以上相关(每10年HR 2.43,p<0.001)。
  • 多因素调整诊断年份、种族、PSA密度和肿瘤体积后,高龄仍相关(每10年HR 2.19,p<0.001)。
  • 穿刺升级后行根治术者,高龄者根治术分级升级率更高(p<0.05)。

临床怎么用

  • 对高龄主动监测患者应加强分级监测,警惕升级至GG3及以上。
  • 高龄患者穿刺升级后根治术病理升级风险更高,需充分告知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Age at prostate cancer diagnosis has been positively associated with prostate cancer specific mortality and in men on active surveillance with a higher risk of biopsy grade reclassification to Gleason score 3 + 4 or greater (Grade Group 2 or greater). However, to our knowledge the association between age and biopsy grade reclassification to an aggressive phenotype (Gleason score 4 + 3 or greater [Grade Group 3 or greater]) has not been explored. MATERIALS AND METHODS: From 1995 to 2016 we followed 1,625 men 41 to 81 years old with NCCN® (National Comprehensive Cancer Network®) very low (68%) or low (32%) risk prostate cancer on active surveillance. We determined the rate of biopsy grade reclassification to Grade Group 3 or greater. Competing risk analysis was applied to evaluate the association between age at enrollment and the risk of biopsy grade reclassification. Additionally, in men who underwent radical prostatectomy after biopsy grade reclassification we assessed the rate of radical prostatectomy grade reclassification (ie radical prostatectomy Grade Group greater than biopsy Grade Group). RESULTS: The 5-year incidence of biopsy grade reclassification to Grade Group 3 or greater was 4%, 7% and 14% in men younger than 60, 60 to 69 and 70 years old or older, respectively (p <0.001). On univariate analysis older age was associated with biopsy grade reclassification to Grade Group 3 or greater (per 10-year increase HR 2.43, p <0.001). On multivariable analysis adjusting for year of diagnosis, race, prostate specific antigen density and cancer volume at diagnosis older age remained associated with biopsy grade reclassification to Grade Group 3 or greater (per 10-year increase HR 2.19, p <0.001). In men who underwent radical prostatectomy after biopsy grade reclassification those who were older had a higher rate of radical prostatectomy grade reclassification (p <0.05). CONCLUSIONS: In men on active surveillance older age at diagnosis was positively associated with biopsy grade reclassification to Grade Group 3 or greater and radical prostatectomy grade reclassification. These observations imply that for many older men, active surveillance as opposed to watchful waiting remains a more appropriate management strategy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Druskin SC, Mamawala M, Tosoian JJ, et al. Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance. J Urol. 2019. PMID: 30114397. doi:10.1016/j.juro.2018.08.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。